![Alexandra MacLean](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alexandra MacLean
Directeur Général chez AVENUE THERAPEUTICS, INC.
Fortune : - $ au 31/05/2024
Profil
Alexandra MacLean is currently the Chief Executive Officer & Director at Avenue Therapeutics, Inc. She is also a Director at Access Vascular, Inc. Previously, she worked as an Entrepreneur in Residence at Fortress Biotech, Inc. from 2021 to 2022.
She also held the position of Head-Licensing & Business Development at Imbrium Therapeutics LP.
Dr. MacLean holds a graduate degree from the University of Cambridge, an undergraduate degree from McGill University, an MBA from the University of Colorado Boulder, and a doctorate from Vagelos College of Physicians & Surgeons.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
06/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Alexandra MacLean
Sociétés | Poste | Début |
---|---|---|
AVENUE THERAPEUTICS, INC. | Directeur Général | 01/08/2022 |
Access Vascular, Inc.
![]() Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Alexandra MacLean
Sociétés | Poste | Fin |
---|---|---|
FORTRESS BIOTECH, INC. | Corporate Officer/Principal | 01/07/2022 |
Imbrium Therapeutics LP
![]() Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Corporate Officer/Principal | - |
Formation de Alexandra MacLean
University of Cambridge | Graduate Degree |
McGill University | Undergraduate Degree |
University of Colorado Boulder | Masters Business Admin |
Vagelos College of Physicians & Surgeons | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
FORTRESS BIOTECH, INC. | Health Technology |
AVENUE THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Access Vascular, Inc.
![]() Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Health Technology |
Imbrium Therapeutics LP
![]() Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |